Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
Kruit
W H J
WH
Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus Medical Center, Rotterdam, The Netherlands. w.kruit@erasmusmc.nl
Stoter
G
G
Klijn
J G M
JG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000616:Aminoglutethimide / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016001:Confidence Intervals; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D000616:Aminoglutethimide; D017430:Prostate-Specific Antigen; D006854:Hydrocortisone